Apricus Biosciences Closes $3.7 Million Registered Direct Offering
(Thomson Reuters ONE) -
SAN DIEGO, Sept. 28, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
(Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in
urology and rheumatology, today announced that it has closed a registered direct
offering of shares of common stock with institutional investors for gross
proceeds of approximately $3.7 million. Based on feedback from the Nasdaq stock
market, Apricus and the investors mutually agreed to revise the size of the
offering such that fewer shares of common stock were issued than previously
announced. The purchase price per share remained the same.
The Company issued approximately 10.8 million registered shares of common stock
at a purchase price of $0.345 per share. Concurrently in a private placement,
for each share of common stock purchased by an investor, such investor received
from the Company an unregistered warrant to purchase 0.75 shares of common
stock. The warrants have an exercise price of $0.45 per share, will be
exercisable six (6) months following the closing date and will expire 5 years
from the initial exercise date.
Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC, acted as the exclusive
placement agent in connection with this offering.
The Company intends to use the net proceeds from the offering for working
capital and general corporate purposes.
The sale of shares of common stock and warrants was made pursuant to a
securities purchase agreement, dated September 27, 2016, by and among the
Company and the investors. The Company and the investors terminated the
previously announced securities purchase agreement, dated September 22, 2016,
prior to the closing in order to complete an at the market offering for purposes
of the Nasdaq listing rules.
The shares of common stock described above (but not the warrants or the shares
of common stock underlying the warrants) are being offered pursuant to a shelf
registration statement (File No. 333-198066). Such shares of common stock may
be offered only by means of a prospectus, including a prospectus supplement,
forming a part of the effective registration statement.
The warrants and the shares of common stock underlying the warrants issued in
the offering have not been registered under the Securities Act of 1933, as
amended or applicable state securities laws. Accordingly, the warrants and
underlying shares of common stock may not be offered or sold in the United
States except pursuant to an effective registration statement or an applicable
exemption from the registration requirements of the Securities Act and such
applicable state securities laws.
This press release shall not constitute an offer to sell or the solicitation of
an offer to buy any of the securities described herein. There shall not be any
offer, solicitation of an offer to buy, or sale of securities in any state or
jurisdiction in which such an offering, solicitation, or sale would be unlawful
prior to registration or qualification under the securities laws of any such
state or jurisdiction. On September 28, 2016, the Company filed a prospectus
supplement with the SEC relating to such shares of common stock, and copies of
the prospectus supplement and the accompanying base prospectus relating to this
offering may be obtained at the SEC's website at http://www.sec.gov, or from
H.C. Wainwright & Co. by e-mailingplacements(at)hcwco.com.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing
innovative medicines in urology and rheumatology. Apricus' commercial product,
Vitaros®, for the treatment of erectile dysfunction, is approved in Canada and
certain countries in Europe, Latin America and the Middle East and is being
commercialized in several countries in Europe. In September 2015, Apricus in-
licensed the U.S. development and commercialization rights for Vitaros from
Allergan. Apricus' marketing partners for Vitaros include Recordati Ireland Ltd.
(Recordati), Ferring International Center S.A. (Ferring Pharmaceuticals),
Laboratoires Majorelle, Bracco S.p.A., Mylan NV and Elis Pharmaceuticals Ltd.
Apricus currently has one active product candidate, RayVa(TM), its product
candidate for the treatment of the circulatory disorder Raynaud's phenomenon.
For further information on Apricus, visit http://www.apricusbio.com.
*Vitaros® is a registered trademark of NexMed International Limited. Such
trademark is registered in certain countries throughout the world and pending
registration in the United States.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act, as amended. Statements in this press
release that are not purely historical are forward-looking statements. Such
forward-looking statements include, among other things: Apricus' expectations on
the anticipated use of proceeds from the offering. Actual results could differ
from those projected in any forward-looking statements due to a variety of
reasons that are outside the control of Apricus, including, but not limited to:
Apricus' dependence on its commercial partners to carry out the commercial
launch or grow sales of Vitaros in various territories and the potential for
delays in the timing of commercial launches in additional countries; competition
in the erectile dysfunction market and other markets in which Apricus and its
partners operate; Apricus' ability to obtain FDA and other requisite
governmental approval for Vitaros; Apricus' ability to comply with Nasdaq
listing requirements; and other risks and uncertainties inherent in Apricus'
business, including those described in the Company's periodic filings with the
SEC and the prospectus supplement and related prospectus for this offering filed
with the SEC. These forward-looking statements are made as of the date of this
press release, and Apricus assumes no obligation to update the forward-looking
statements, or to update the reasons why actual results could differ from those
projected in the forward-looking statements. Readers are urged to read the risk
factors set forth in Apricus' most recent annual report on Form 10-K, subsequent
quarterly reports filed on Form 10-Q, and other filings made with the SEC.
Copies of these reports are available from the SEC's website at www.sec.gov or
without charge from Apricus.
Investor Relations Contact:
Matthew Beck
mbeck(at)troutgroup.com
The Trout Group
(646) 378-2933
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Apricus Biosciences, Inc. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 29.09.2016 - 01:00 Uhr
Sprache: Deutsch
News-ID 497737
Anzahl Zeichen: 7527
contact information:
Town:
SAN DIEGO
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 241 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Apricus Biosciences Closes $3.7 Million Registered Direct Offering"
steht unter der journalistisch-redaktionellen Verantwortung von
Apricus Biosciences, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
